According to a recent survey by Verpora that will be presented this week at ISPOR, nearly half of U.S. payers surveyed expressed a belief that wider implementation of innovative contracts could lead to lower patient out-of-pocket costs across small molecule, biologic, cell and gene therapies. This echoes the support biopharmaceutical companies have for these innovative contracts, and recent studies that demonstrate the potential impact value-based approaches can have on improving patient health outcomes, decreasing payer costs and lowering patient out-of-pocket spending.
